ProShares Ultra NASDAQ Biotechnology
35 hedge funds and large institutions have $28.7M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
37% more capital invested
Capital invested by funds: $21M → $28.7M (+$7.76M)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
13% more funds holding
Funds holding: 31 → 35 (+4)
1% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $17.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
+$4.04M |
| 2 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
+$2.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.77M |
| 4 |
BA
BKS Advisors
Southfield,
Michigan
|
+$1.76M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.79M |
| 2 |
VF
Virtu Financial
New York
|
-$2.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.61M |
| 4 |
RIA
RPG Investment Advisory
Pleasanton,
California
|
-$850K |
| 5 |
Jane Street
New York
|
-$663K |
BIB Hedge Fund Activity: Q3 2016 in Review
35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2016, worth a combined $28.7M — up 37% from $21M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BIB positions and 7 closed out — a net gain of 5 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Opus Point Partners Management, opening a new position worth an estimated $4.04M. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.79M.
- 35 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2016, up from 31 in Q2 2016.
- Funds reported $28.7M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2016, up 37% quarter-over-quarter.
- 12 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2016 and 7 closed out, a net change of +5 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2016 was Opus Point Partners Management, an estimated $4.04M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2016 was Tower Research Capital (TRC), an estimated $2.79M sold.
Based on aggregated 13F filings for Q3 2016.